Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797100871835713536 |
|---|---|
| author | Briasoulis, A Tousoulis, D Papageorgiou, N Kampoli, A Androulakis, E Antoniades, C Tsiamis, E Latsios, G Stefanadis, C |
| author_facet | Briasoulis, A Tousoulis, D Papageorgiou, N Kampoli, A Androulakis, E Antoniades, C Tsiamis, E Latsios, G Stefanadis, C |
| author_sort | Briasoulis, A |
| collection | OXFORD |
| description | Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition. |
| first_indexed | 2024-03-07T05:43:49Z |
| format | Journal article |
| id | oxford-uuid:e680a764-4302-414a-8fb4-bd7261c87560 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:43:49Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:e680a764-4302-414a-8fb4-bd7261c875602022-03-27T10:31:39ZNovel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e680a764-4302-414a-8fb4-bd7261c87560EnglishSymplectic Elements at Oxford2012Briasoulis, ATousoulis, DPapageorgiou, NKampoli, AAndroulakis, EAntoniades, CTsiamis, ELatsios, GStefanadis, CMatrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition. |
| spellingShingle | Briasoulis, A Tousoulis, D Papageorgiou, N Kampoli, A Androulakis, E Antoniades, C Tsiamis, E Latsios, G Stefanadis, C Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title | Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title_full | Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title_fullStr | Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title_full_unstemmed | Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title_short | Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. |
| title_sort | novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease |
| work_keys_str_mv | AT briasoulisa noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT tousoulisd noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT papageorgioun noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT kampolia noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT androulakise noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT antoniadesc noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT tsiamise noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT latsiosg noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease AT stefanadisc noveltherapeuticapproachestargetingmatrixmetalloproteinasesincardiovasculardisease |